ZLDPFPNKHealthcare

Zealand Pharma A/S

Reports in 8d· 2026-05-07

-27.7% · 90d

$49.00

+1.53 (+3.22%)

News

No News Yet

Press releases and SEC filings for ZLDPF will appear here as they are published.

Check back later for updates

Key Data

Market Cap$3.50B

Open$49.00

Prev Close$47.47

Day Range$49.00 – $49.00

52W Range$35.93 – $83.12

Volume100

P/E (TTM)3.47

EPS$14.13

Dividend Yield—

Beta0.57

Profit Margin70.05%

Revenue Growth661.00%

Next Earnings2026-05-07(8d)

About

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

Healthcare · Biotechnology

481 employees

www.zealandpharma.com

Top Institutional Holders

As of 2024-09-30

Pacer Advisors, Inc.$243

2 sh● NEW

See all holders →